Detection of Extended Spectrum $\beta$-lactamase Production Among Uropathogens

Ritu Aggarwal, Uma Chaudhary, Rama Sikka

Department of Microbiology, Pt. B.D.Sharma Post Graduate Institute of Medical Sciences, Rohtak-124 001, Haryana, India

Address for correspondence: Dr. Ritu Aggarwal, E-mail: drritu252@yahoo.com

ABSTRACT

Background: Detection of extended spectrum $\beta$-lactamase (ESBL) production among uropathogens is an important marker of endemicity.

Aim: Intervention of this endemic transmission is important for the control of initial outbreak of ESBL producing organisms in a hospital or specialized unit of hospital.

Materials and Methods: During the study period of one and a half months, 1,551 urine samples were processed for significant bacteriuria. Two hundred gram negative bacterial isolates were tested for ESBL production. Antimicrobial sensitivity pattern was ascertained for ESBL producing isolates.

Results: ESBL production was seen in 36% of isolates. All the isolates were multidrug resistant with uniform sensitivity to imipenem.

Conclusion: This study reveals the significant prevalence of ESBL producing organisms in this north Indian tertiary care hospital. Constant revision of antibiotic policies with infection control interventions is suggested.

Keywords: ESBL, endemicity, infection, uropathogens

INTRODUCTION

Extended spectrum $\beta$-lactamase (ESBL) isolates were first detected in western Europe in the mid-1980s. Since then, their incidence has been increasing steadily. A large number of outbreaks of infections due to ESBL producing organisms have been described on every continent of the globe. In some hospitals, initial outbreaks of infections have been supplanted by endemicity of the ESBL producing organisms. This may lead to increased patient mortality when antibiotics inactive against ESBL producers are used. Therefore, control of the initial outbreak of ESBL producing organisms in a hospital or specialized unit of a hospital is of critical importance.[1-3]

Special efforts should be undertaken by clinical microbiology laboratories as recommended by the Clinical and Laboratory Standards Institute (CLSI) for ESBL detection. Additional use of ESBL detection methods has originated because some ESBL producing organisms appeared susceptible to cephalosporins, using conventional breakpoints. It has been recommended that physicians should avoid all penicillins, aztreonam, and cephalosporins if an ESBL producing organism is present.[1-3]

Detection of ESBL producing organism from samples such as urine may be important because this represents an epidemiologic marker of colonization, and therefore there is potential for transfer of such organisms to other patients.[1] Hence, the present study was designed to detect ESBL production among uropathogens.

MATERIALS AND METHODS

The present study was conducted in the Department of Microbiology which is a part of 1,300 bedded teaching tertiary care hospital in India. During one and a half months study period, a total of 1,551 urine samples received in the microbiology laboratory were processed following standard protocol.[4] All the gram negative bacilli (GNB) isolated in significant numbers were identified by standard microbiological procedures...
and sensitivity to third generation cephalosporins (3GC, ceftazidime, ceftriaxone, and cefotaxime) was determined by disc diffusion technique.[3] Results were interpreted according to CLSI guidelines.[6] Escherichia coli ATCC 25922 was used as control strain.

ESBL detection

The ESBL detection in all 200 urinary isolates was done using double disc synergy test as described by Jarlier et al.[4] Synergy was determined between a disc of amoxiclav (20 µg amoxicillin and 10 µg clavulanic acid) and 30 µg disc of each third generation cephalosporin (3GC) test antibiotic placed at a distance of 15 mm apart.

Table 1: Prevalence of ESBL production among GNB isolates from urine (n=200)

| GNB isolated                | Isolates n (%) | ESBL producers n (%) |
|-----------------------------|----------------|----------------------|
| E. coli                     | 100 (50)       | 40 (40)              |
| Klebsiella spp.             | 33 (16.50)     | 18 (54.54)           |
| Pseudomonas aeruginosa      | 23 (11.50)     | 7 (25)               |
| Enterobacter spp.           | 19 (9.50)      | 5 (26.31)            |
| Proteus spp.                | 13 (6.50)      | 0 (0)                |
| Citrobacter spp.            | 9 (4.50)       | 4 (44.44)            |
| Acinetobacter spp.          | 3 (1.50)       | 0 (0)                |

Table 2: ESBL production among 3GC resistant and susceptible group

| Group                     | Number | ESBL +ve n (%) |
|---------------------------|--------|----------------|
| Resistant group           | 122    | 60 (49.18)     |
| Sensitive group           | 78     | 12 (15.38)     |
| Total                     | 200    | 72 (36.00)     |

Table 3: Antimicrobial susceptibility pattern of ESBL producing urinary isolates (n = 72)

| Drug                     | Sensitive n (%) | Resistant n (%) |
|--------------------------|-----------------|-----------------|
| Azlocillin (30 µg)       | 13 (58.05)      | 9 (41.95)       |
| Ticarcillin (75 µg)      | 27 (37.49)      | 45 (62.50)      |
| Cephalothin (30 µg)      | 23 (31.93)      | 49 (68.07)      |
| Cefoperazone (75 µg)     | 44 (61.11)      | 28 (38.88)      |
| Cefamandole (30 µg)      | 25 (34.72)      | 47 (65.27)      |
| Cefoxitin (30 µg)        | 25 (34.72)      | 47 (65.27)      |
| Cephalexin (30 µg)       | 25 (34.72)      | 47 (65.27)      |
| Ampicillin / sulbactam (15/10 µg) | 39 (54.17) | 33 (45.85) |
| Ticarcillin / clavulanate (75/10 µg) | 35 (48.61) | 37 (51.38) |
| Imipenem (10 µg)         | 72 (100)        | –               |
| Lomefloxacin (30 µg)     | 24 (33.33)      | 48 (66.66)      |
| Ofloxacin (5 µg)         | 54 (75)         | 18 (25)         |
| Netilmicin (10 µg)       | 25 (34.72)      | 47 (65.27)      |
| Tobramycin (10 µg)       | 25 (34.72)      | 47 (65.27)      |
| Ceftriaxone (75 µg)      | 7 (10.29)       | 60 (89.55)      |
| Cefotaxime (75 µg)       | 7 (10.29)       | 60 (89.55)      |
| Cotrimoxazole* (30 µg)   | 37 (54.17)      | 30 (45.83)      |
| Nalidixic acid* (30 µg)  | 37 (54.17)      | 30 (45.83)      |
| Nitrofurantoin* (300 µg) | 21 (31.93)      | 46 (68.07)      |
| Norfloxacin* (10 µg)     | 37 (54.17)      | 30 (45.83)      |

*These antibiotics were not tested against P. aeruginosa (n = 67).

RESULTS

A total of 1,551 urine samples from both outdoor and indoor patients were included during one and a half months study period. Out of these 1,551 samples, 226 (14.5%) urine samples yielded significant growth. Amongst these 226 isolates, 26 (11.5%) were gram positive bacteria and yeast isolates. These were excluded from the study. Amongst the remaining 200 (88.49%) gram negative bacterial isolates, 100 were E. coli (50%), 33 were Klebsiella spp. (16.50%), 23 were Pseudomonas aeruginosa (11.50%), 19 were Enterobacter spp. (9.50%), 13 were Proteus spp. (6.50%), nine were Citrobacter spp. (4.50%), and three were Acinetobacter spp. (1.50%). Maximum ESBL production was observed in Klebsiella spp. with 18 (54.54%) strains being ESBL producers. Though E. coli was the most commonly isolated organism from the urine but ESBL production was lower (40%) than Klebsiella spp. Out of only nine Citrobacter spp.
52 (72.72%) were obtained from hospitalized patients, 12 (16.66%) of these patients had been catheterized with Foley’s catheter, prior surgery had been performed in eight (11.11%) of these patients and five (6.94%) of these patients had stayed in ICU.

**DISCUSSION**

Since their appearance in Germany in the early 1980s, ESBL producing bacteria have increased both in variety and number.[9] Earlier they were isolated from hospitalized patients only but now reports of isolation from outdoor patients have started coming.[9]

In the present study, 200 GNB isolates from urine were included. It was observed that 72 (36%) isolates were ESBL producers. A higher incidence, i.e. 58% ESBL production amongst GNB isolates has been reported by other workers.[10] However, the incidence of 39.90% ESBL production reported by other investigators is in accordance with the present study.[11] Other workers have reported lower rates of ESBL production.[12,13] This geographical difference may be due to different patterns of antibiotic use and differences in the selection of organisms for the study.

Earlier, in vitro resistance to third generation cephalosporin was considered to be suomotto evidence of ESBL production. In our study, 15.38% of susceptible isolates were found to be ESBL producers. Similar findings have also been reported by other Indian workers.[14,15] These studies highlighted the fact that some ESBL producing isolates show false susceptibility to third generation cephalosporin in in-vitro testing. These patients are at a risk of poor outcome if they are treated with antimicrobials to which the organisms exhibit high level of resistance. Mortality rates in these susceptibility - treatment mismatched patients has ranged from 42 to 100%. Therefore, it is recommended that specific tests should be undertaken for detection of ESBL where suspicion for such isolates is high.[12,18]

In this study, 100% sensitivity to imipenem was observed. This finding is in concordance with the studies conducted by other workers.[11,13,16-18] Ofloxacin was also found to be a highly effective drug in-vitro. Carbapenems and fluoroquinolones can be alternative to the 3GC for the treatment of serious infections due to ESBL positive GNB.[2,19,20]

In earlier studies, prolonged hospitalization, Foley’s catheterization, prior surgery, and ICU stay were found to be risk factors.[1-3] Good infection control practices and antibiotic management interventions are instrumental in preventing the emergence of outbreaks due to ESBL producing isolates, especially in high risk areas such as the medical ICU, the neonatal ICU, and oncology units. Educational programs for medical staff to increase awareness of ESBLs should also be developed.

Our study confirms the global trend toward increased resistance to β-lactam antibiotics. It is emphasized that institutions with high prevalence of third generation cephalosporin resistant organisms should employ appropriate tests for their detection and avoid indiscriminate use of third generation cephalosporins. Moreover, the prevalence and antibiotic susceptibility pattern of ESBL producers differs geographically. Hence, such institutional studies will help in the formulation of antibiotic policy for a particular geographical area.

**REFERENCES**

1. Paterson DL, Bonomo RA. Extended spectrum β-lactamases: a clinical update. Clin Microbiol Rev 2005;18:657-86.
2. Nathisuwan S, Burgess DS, Lewis JS 2nd. Extended Spectrum β-lactamases: Epidemiology, Detection and treatment. Pharmacotherapy 2001;21:920-8.
3. Rupp ME, Fey PD. Extended Spectrum β-lactamase (ESBL) – Producing Enterobacteriaceae. Drugs 2003;63:353-65.
4. Duguid JP, Collee JG, Fraser AG. Laboratory strategy in the diagnosis of infective syndromes. In: Collee JG, Duguid JP, Fraser AG, Marmion BP, editors. Mackie and MacCartney: Practical Medical Microbiology. 13th ed. Singapore: Longman Singapore Publishers; 1989. p. 600-49.
5. Bauer AW, Kirby W, Sherris J, Turk M. Antibiotic susceptibility testing by a standard single disc method. Am J Clin Pathol 1996;45:493-6.
6. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility: sixteenth informational supplement. Wayne, PA, USA:CLSI: 2006; M100-S16.
7. Gupta N, Yadav A, Choudhary U, Arora DR. Citrobacter bacteremia in a tertiary care hospital. Scand J Infect Dis 2003;35:765-8.
8. Ananthkrishnan AN, Kanungo R, Kumar A, Badrinath S. Detection of extended spectrum beta lactamase producers among surgical wound infections and burn patients in JIPMER. Ind J Med Microbiol 2000;18:160-5.
9. Brigante G, Luzzaro F, Perilli M, Lombardi G, Coli A, Rossolini GM, et al. Evolution of CTX-M type beta –lactamases in isolates of Escherichia coli infecting hospital and community patients. Int J Antimicrob Agents 2005;25:157-62.
10. Mathur P, Kapil A, Das B, Dhawan B. Prevalence of extended spectrum β-lactamase producing gram negative bacteria in a tertiary care hospital. Scand J Infect Dis 2003;35:765-8.
11. Ananthkrishnan AN, Kanungo R, Kumar A, Badrinath S. Detection of extended spectrum beta lactamase producers among surgical wound infections and burn patients in JIPMER. Ind J Med Microbiol 2000;18:160-5.
12. Babypadmini S, Appalaraju B. Extended spectrum β-lactamases in urinary isolates of Escherichia coli and Klebsiella pneumoniae - Prevalence and susceptibility pattern in a tertiary care hospital.. Indian J Med Microbiol 2004;22:172-4.
13. Shukla I, Tiwari R, Agrawal M. Prevalence of extended spectrum β-lactamases producing Klebsiella pneumoniae in Chennai. Indian J Med Microbiol 2002;20:92-5.
14. Shukla I, Tiwari R, Agrawal M. Prevalence of extended spectrum β-lactamases producing Klebsiella pneumoniae in Chennai. Indian J Med Microbiol 2002;20:92-5.
15. Uma A, Mehta A, Ayyagari A, Kapil A, Shahnvi A, Rodrigues C et al.
Prevalence of β-lactamase producing strains among clinical isolates obtained from hospital in patients across India and comparison of anti-bacterial susceptibility using disc diffusion method. EGAST 2000. Hospital Today 2004;9:70-80.

16. Peña C, Pujol M, Ardanuy C, Ricart A, Pallares R, Liñares J, et al. Epidemiology and successful control of a large outbreak due to *Klebsiella pneumoniae* producing extended spectrum β-lactamases. Antimicrob Agents Chemother 1998;42:53-8.

17. Winokur PL, Canton R, Casellas JM, Legakis N. Variations in the prevalence of strains expressing an extended-spectrum beta-lactamase phenotype and characterization of isolates from Europe, the Americas, and the Western Pacific region. Clin Infect Dis 2001;32:S94-103.

18. Hansotia JB, Agarwal V, Parhak AA, Saoji AM. Extended spectrum β-lactamase mediated resistance to third generation cephalosporins in Nagpur, Central India. Indian J Med Res 1997;105:153-61.

19. Paterson DL, Recommendations for treatment of severe infections caused by Enterobacteriaceae producing extended spectrum β-lactamase (ESBL). Clin Microbiol Infect 2000;6:460-3.

20. Karas JA, Pillay DG, Muckart D, Sturm AW. Treatment failure due to extended spectrum β-lactamase. J Antimicrob Chemother 1996;37:203-4.

Source of Support: Nil, Conflict of Interest: None declared.

**Author Help: Online submission of the manuscripts**

Articles can be submitted online from http://www.journalonweb.com. For online submission, the articles should be prepared in two files (first page file and article file). Images should be submitted separately.

1) **First Page File:**
Prepare the title page, covering letter, acknowledgement etc. using a word processor program. All information related to your identity should be included here. Use text/rtf/doc/pdf files. Do not zip the files.

2) **Article File:**
The main text of the article, beginning with the Abstract to References (including tables) should be in this file. Do not include any information (such as acknowledgement, your names in page headers etc.) in this file. Use text/rtf/doc/pdf files. Do not zip the files. Limit the file size to 400 kb. Do not incorporate images in the file. If file size is large, graphs can be submitted separately as images, without their being incorporated in the article file. This will reduce the size of the file.

3) **Images:**
Submit good quality color images. Each image should be less than 1024 kb (1 MB) in size. The size of the image can be reduced by decreasing the actual height and width of the images (keep up to about 6 inches and up to about 1200 pixels) or by reducing the quality of image. JPEG is the most suitable file format. The image quality should be good enough to judge the scientific value of the image. For the purpose of printing, always retain a good quality, high resolution image. This high resolution image should be sent to the editorial office at the time of sending a revised article.

4) **Legends:**
Legends for the figures/images should be included at the end of the article file.